BiotechTube

Anti-PDL-1 antibody + Anti-PDL-1 antibody + Anti-PDL-1 antibody + Anti-PDL-1 antibody + Anti-PDL-1 antibody

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cancer, Multiple Indications

Conditions

Cancer, Multiple Indications

Trial Timeline

Feb 1, 2009 → Jul 1, 2015

NCT ID
NCT00729664

About Anti-PDL-1 antibody + Anti-PDL-1 antibody + Anti-PDL-1 antibody + Anti-PDL-1 antibody + Anti-PDL-1 antibody

Anti-PDL-1 antibody + Anti-PDL-1 antibody + Anti-PDL-1 antibody + Anti-PDL-1 antibody + Anti-PDL-1 antibody is a phase 1 stage product being developed by Bristol Myers Squibb for Cancer, Multiple Indications. The current trial status is completed. This product is registered under clinical trial identifier NCT00729664. Target conditions include Cancer, Multiple Indications.

What happened to similar drugs?

20 of 20 similar drugs in Cancer, Multiple Indications were approved

Approved (20) Terminated (4) Active (0)
✅arzoxifeneEli LillyApproved
✅EnzalutamideAstellas PharmaApproved
✅EnzalutamideAstellas PharmaApproved
✅Enzalutamide + Androgen deprivation therapy (ADT)Astellas PharmaApproved
✅Enzalutamide + Abiraterone + Placebo for Enzalutamide + PrednisoneAstellas PharmaApproved
✅EnzalutamideAstellas PharmaApproved
✅Enzalutamide + FlutamideAstellas PharmaApproved

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00729664Phase 1Completed

Competing Products

20 competing products in Cancer, Multiple Indications

See all competitors
ProductCompanyStageHype Score
E7389EisaiPhase 1
29
VeliparibAbbViePhase 2
27
AK-105AkesoPhase 1
29
XL820ExelixisPhase 1
26
LymphoseekNavidea BiopharmaceuticalsPhase 3
30
LymphoseekNavidea BiopharmaceuticalsPhase 3
30
ALT-P7 (HM2-MMAE)AlteogenPhase 1
29
pegylated liposomal doxorubicin (PLD) + PD-1CSPC Pharmaceutical Group LimitedPhase 2
31
Biomarkers blood, urine and microbiota samplesEli LillyPre-clinical
30
gemcitabine + paclitaxel + bevacizumabEli LillyPhase 2
35
pemetrexedEli LillyPhase 2
27
LY3300054 + PrexasertibEli LillyPhase 1
29
BBP-398 with nivolumabBridgeBio PharmaPhase 1
18
Cetuximab + Oxaliplatin + CapecitabineEli LillyPhase 2
35
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
27
Gemcitabine + Adriamycine + PaclitaxelEli LillyPhase 2
35
SelpercatinibEli LillyPre-clinical
26
Pemetrexed + Cisplatin + Placebo + PemetrexedEli LillyPhase 3
40
NBTXR3 activated by IMRT only + NBTXR3 activated by Brachytherapy & IMRTNanobiotixPhase 1/2
18
NBTXR3NanobiotixPhase 1/2
33